TScan Therapeutics (TCRX) to Release Quarterly Earnings on Monday

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $1.62 million for the quarter.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.02. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The business had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.62 million. On average, analysts expect TScan Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TScan Therapeutics Stock Up 2.6 %

NASDAQ:TCRX traded up $0.04 during trading hours on Wednesday, reaching $1.40. 235,729 shares of the stock were exchanged, compared to its average volume of 361,136. The stock has a market cap of $78.94 million, a PE ratio of -1.32 and a beta of 1.06. TScan Therapeutics has a twelve month low of $1.02 and a twelve month high of $9.69. The firm has a 50 day moving average of $1.52 and a 200 day moving average of $2.78. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56.

Wall Street Analyst Weigh In

TCRX has been the topic of several analyst reports. Barclays cut their price target on shares of TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating on the stock in a research report on Friday, March 7th. Needham & Company LLC reiterated a "buy" rating and set a $9.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, April 8th. HC Wainwright decreased their target price on shares of TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday. Morgan Stanley restated an "overweight" rating and set a $10.00 target price on shares of TScan Therapeutics in a report on Friday, March 14th. Finally, Wedbush reissued an "outperform" rating and issued a $7.00 price objective on shares of TScan Therapeutics in a research report on Tuesday. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, TScan Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $8.50.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.